Laparoscopic liver resection for non-colorectal non-neuroendocrine metastases: perioperative and oncologic outcomes.
Adenocarcinoma
/ mortality
Adrenal Cortex Neoplasms
/ mortality
Adrenocortical Carcinoma
/ mortality
Aged
Carcinoma, Squamous Cell
/ mortality
Female
Follow-Up Studies
Gastrointestinal Neoplasms
/ mortality
Gastrointestinal Stromal Tumors
/ mortality
Hepatectomy
/ mortality
Humans
Laparoscopy
/ mortality
Liver Neoplasms
/ mortality
Male
Melanoma
/ mortality
Middle Aged
Perioperative Care
Prognosis
Prospective Studies
Retrospective Studies
Sarcoma
/ mortality
Survival Rate
Laparoscopic liver surgery
Non-colorectal
Non-neuroendocrine liver metastases
Survival
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
04 Sep 2019
04 Sep 2019
Historique:
received:
07
06
2019
accepted:
28
08
2019
entrez:
6
9
2019
pubmed:
6
9
2019
medline:
13
2
2020
Statut:
epublish
Résumé
Liver resection is a treatment of choice for colorectal and neuroendocrine liver metastases, and laparoscopy is an accepted approach for surgical treatment of these patients. The role of liver resection for patients with non-colorectal non-neuroendocrine liver metastases (NCNNLM), however, is still disputable. Outcomes of laparoscopic liver resection for this group of patients have not been analyzed. In this retrospective study, patients who underwent laparoscopic liver resection for NCNNLM at Oslo University Hospital between April 2000 and January 2018 were analyzed. Perioperative and oncologic data of these patients were examined. Postoperative morbidity was classified using the Accordion classification. Kaplan-Meier method was used for survival analysis. Median follow-up was 26 (IQR, 12-41) months. Fifty-one patients were identified from a prospectively collected database. The histology of primary tumors was classified as adenocarcinoma (n = 16), sarcoma (n = 4), squamous cell carcinoma (n = 4), melanoma (n = 16), gastrointestinal stromal tumor (n = 9), and adrenocortical carcinoma (n = 2). The median operative time was 147 (IQR, 95-225) min, while the median blood loss was 200 (IQR, 50-500) ml. Nine (18%) patients experienced postoperative complications. There was no 90-day mortality in this study. Thirty-five (68%) patients developed disease recurrence or progression. Seven (14%) patients underwent repeat surgical procedure for recurrent liver metastases. One-, three-, and five-year overall survival rates were 85%, 52%, and 38%, respectively. The median overall survival was 37 (95%CI, 25 to 49) months. Laparoscopic liver resection for NCNNLM results in good outcomes and should be considered in patients selected for surgical treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Liver resection is a treatment of choice for colorectal and neuroendocrine liver metastases, and laparoscopy is an accepted approach for surgical treatment of these patients. The role of liver resection for patients with non-colorectal non-neuroendocrine liver metastases (NCNNLM), however, is still disputable. Outcomes of laparoscopic liver resection for this group of patients have not been analyzed.
MATERIAL AND METHODS
METHODS
In this retrospective study, patients who underwent laparoscopic liver resection for NCNNLM at Oslo University Hospital between April 2000 and January 2018 were analyzed. Perioperative and oncologic data of these patients were examined. Postoperative morbidity was classified using the Accordion classification. Kaplan-Meier method was used for survival analysis. Median follow-up was 26 (IQR, 12-41) months.
RESULTS
RESULTS
Fifty-one patients were identified from a prospectively collected database. The histology of primary tumors was classified as adenocarcinoma (n = 16), sarcoma (n = 4), squamous cell carcinoma (n = 4), melanoma (n = 16), gastrointestinal stromal tumor (n = 9), and adrenocortical carcinoma (n = 2). The median operative time was 147 (IQR, 95-225) min, while the median blood loss was 200 (IQR, 50-500) ml. Nine (18%) patients experienced postoperative complications. There was no 90-day mortality in this study. Thirty-five (68%) patients developed disease recurrence or progression. Seven (14%) patients underwent repeat surgical procedure for recurrent liver metastases. One-, three-, and five-year overall survival rates were 85%, 52%, and 38%, respectively. The median overall survival was 37 (95%CI, 25 to 49) months.
CONCLUSION
CONCLUSIONS
Laparoscopic liver resection for NCNNLM results in good outcomes and should be considered in patients selected for surgical treatment.
Identifiants
pubmed: 31484583
doi: 10.1186/s12957-019-1700-y
pii: 10.1186/s12957-019-1700-y
pmc: PMC6727573
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
156Références
J Laparoendosc Adv Surg Tech A. 2001 Jun;11(3):133-9
pubmed: 11441989
Ann Surg. 2002 Jul;236(1):90-7
pubmed: 12131090
J Hepatobiliary Pancreat Surg. 2005;12(4):298-303
pubmed: 16133696
Semin Oncol. 2005 Dec;32(6 Suppl 9):S109-11
pubmed: 16399446
Ann Surg. 2006 Oct;244(4):524-35
pubmed: 16998361
Ann Surg. 2008 Jan;247(1):125-35
pubmed: 18156932
HPB (Oxford). 2007;9(6):435-9
pubmed: 18345290
Ann Surg. 2009 Aug;250(2):177-86
pubmed: 19638919
Arch Surg. 2010 Jan;145(1):34-40
pubmed: 20083752
J Am Coll Surg. 2010 Mar;210(3):286-98
pubmed: 20193891
HPB (Oxford). 2011 Apr;13(4):286-92
pubmed: 21418135
Scand J Surg. 2011;100(1):54-65
pubmed: 21482506
Cancer. 2012 Jul 15;118(14):3571-8
pubmed: 22086856
J Am Coll Surg. 2012 May;214(5):769-77
pubmed: 22425166
Surg Oncol. 2012 Sep;21(3):e131-41
pubmed: 22658833
Surgery. 2012 Dec;152(6):1225-31
pubmed: 23068086
Lancet Oncol. 2013 Nov;14(12):1208-15
pubmed: 24120480
HPB (Oxford). 2014 Sep;16(9):822-9
pubmed: 24308605
Langenbecks Arch Surg. 2014 Dec;399(8):989-1000
pubmed: 25148767
PLoS One. 2014 Dec 08;9(12):e114404
pubmed: 25485541
J Gastrointest Surg. 2015 Aug;19(8):1476-83
pubmed: 26001368
Updates Surg. 2015 Jun;67(2):185-91
pubmed: 26109140
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1083-92
pubmed: 26242369
Int J Surg. 2015 Oct;22:136-42
pubmed: 26277530
Neuroendocrinology. 2016;103(2):172-85
pubmed: 26731013
J Gastrointest Surg. 2016 Jun;20(6):1163-72
pubmed: 26921025
ANZ J Surg. 2017 Oct;87(10):810-814
pubmed: 27037839
ANZ J Surg. 2018 Apr;88(4):E313-E317
pubmed: 27490345
Anticancer Res. 2017 Jan;37(1):9-14
pubmed: 28011468
World J Hepatol. 2017 Feb 18;9(5):242-251
pubmed: 28261381
J Gastrointest Surg. 2017 Jun;21(6):1076-1085
pubmed: 28364212
Ann Surg. 2019 Jan;269(1):120-126
pubmed: 28549012
Surg Oncol. 2017 Jun;26(2):146-152
pubmed: 28577720
Ann Surg. 2018 Feb;267(2):199-207
pubmed: 28657937
Gastroenterol Res Pract. 2017;2017:5184146
pubmed: 28811821
J Am Coll Surg. 2017 Nov;225(5):639-649
pubmed: 28838869
World J Surg. 2018 Apr;42(4):1073-1084
pubmed: 28875334
Surg Endosc. 2018 Mar;32(3):1470-1477
pubmed: 28916919
Nat Rev Gastroenterol Hepatol. 2017 Nov;14(11):638-639
pubmed: 28930294
Am J Surg. 2018 Jan;215(1):125-130
pubmed: 29061283
Int J Surg. 2018 Feb;50:35-42
pubmed: 29284151
Radiol Oncol. 2017 Nov 1;52(1):36-41
pubmed: 29520204
Eur J Cancer. 2018 May;95:1-10
pubmed: 29579478
J Hepatobiliary Pancreat Sci. 2018 Nov;25(11):465-475
pubmed: 30311741
Surgery. 1997 Jun;121(6):625-32
pubmed: 9186462